GleamWall
中文EN

MLTX MoonLake Immunotherapeutics

Pharmaceutical Preparations · Nasdaq · SEC CIK 1821586 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-29.9%
TTM EPS YoY-9.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-81.6%
ROA-57.3%
ROIC (approx.)-384.1%
Asset turnover—

Leverage & solvency

Liabilities / assets29.4%
Debt / equity0.26x
Current ratio9.13x
Interest coverage-28.98x

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$68.87M$50.22M$54.52M$56.01M$60.63M$49.76M$36.46M$40.36M
SG&A expense$10.98M$11.44M$15.51M$9.21M$10.80M$10.94M$11.03M$9.22M
Operating income-$79.85M-$61.66M-$70.02M-$65.22M-$71.43M-$60.70M-$47.48M-$49.58M
Interest expense$2.65M$2.63M$2.27M$1.99M$3.20M$2.04M$18,000$0
Income tax$631,000$90,000$622,000$248,000$115,000$95,000$153,000$41,000
Net income-$79.55M-$61.80M-$69.71M-$62.43M-$69.73M-$55.22M-$39.94M-$45.60M
EBITDA-$78.95M-$60.76M-$69.18M-$64.47M-$70.69M-$59.96M-$47.11M-$49.22M
EPS (basic)-0.93-0.84-0.98—-1.10-0.87-0.63—
EPS (diluted)-0.93-0.84-0.98—-1.10-0.87-0.63—
Weighted avg. shares (diluted)85.38M73.92M71.27M—63.37M63.28M63.23M—
Balance sheet
Cash & equivalents$379.70M$477.90M$298.49M$334.52M$350.74M$306.68M$271.57M$180.43M
Short-term investments$118.76M$59.12M$59.43M$59.45M$29.74M$118.40M$208.56M$267.60M
Current assets$533.34M$570.04M$396.64M$421.69M$411.21M$455.48M$506.26M$474.29M
PP&E, net$443,000$487,000$532,000$577,000$622,000$667,000$711,000$722,000
Total assets$540.72M$573.95M$400.37M$424.43M$414.33M$460.10M$511.26M$477.93M
Current liabilities$58.43M$45.39M$46.11M$45.48M$48.37M$27.36M$23.98M$22.46M
Long-term debt$100.01M$99.51M$99.02M$74.10M$73.74M$73.38M$73.02M$0
Total debt$100.01M$99.51M$99.02M$74.10M$73.74M$73.38M$73.02M$0
Total liabilities$159.09M$145.75M$146.35M$119.95M$123.14M$102.15M$98.68M$24.54M
Shareholders' equity$381.63M$428.19M$254.02M$304.48M$288.91M$353.73M$407.52M$446.82M
Net debt-$279.69M-$378.39M-$199.47M-$260.42M-$277.00M-$233.30M-$198.54M-$180.43M
Cash flow statement
Operating cash flow-$63.40M-$55.56M-$66.29M-$58.79M-$44.54M-$54.53M-$38.14M-$48.47M
Capital expenditure$0$0$0$0$0$0$35,000$176,000
Free cash flow-$63.40M-$55.56M-$66.29M-$58.79M-$44.54M-$54.53M-$38.17M-$48.65M
Investing cash flow-$58.76M$322,000$98,000-$29.91M$88.40M$88.25M$56.25M-$147.33M
Financing cash flow$26.97M$234.62M$30.64M$72.39M$480,000$0$73.12M$151,000
Depreciation & amortization$905,000$896,000$845,000$751,000$745,000$742,000$378,000$364,000
Stock-based compensation$2.85M$2.55M$13.36M$3.59M$3.71M$3.31M$2.29M$1.93M
Share buybacks———————$0

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.